ASCO Highlights

Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis

It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]

Sarcoma

Brian Van Tine, ASCO20: Summary of the Phase 1 SPEARHEAD-1 Trial in Sarcoma

Brian Van Tine, Washington University in St. Louis, discusses the data presented at ASCO20 from the Phase I SPEARHEAD-1 study of T-cell receptor therapy ADP-A2M4 in patients with solid tumors previously treated with chemotherapy. Questions 1. What are the major limitations and unmet needs of T cell therapy, especially with the current available CAR-Ts? (0:06) […]

Leukaemia

Mikkael Sekeres, ASCO20: New combination therapy in patients with MDS/CMML or LB AML

It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment […]

Lung Cancer

Ross Camidge: Brigatinib for Adult Patients With ALK+ Metastatic Non-small Cell Lung Cancer

touchONCOLOGY were delighted to speak to Ross Camidge, University of Colorado Cancer Center, to discuss the recent FDA approved of brigatinib for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. Questions 1. What are the unmet needs in the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer? (0:06) […]

Genitourinary Cancers

Axel Merseburger, ASCO20: Clinical Updates in Urothelial Carcinoma and Renal Cell Carcinoma

We are joined by touchONCOLOGY European Oncology & Haematology Editor-in-Chief Dr Axel S Merseburger to discuss his highlights from the JAVELIN Bladder 100 Trial (Clinicaltrials.gov identifier: NCT02603432) and the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma (ClinicalTrials.gov identifier: NCT02853331). Questions 1. What are the current unmet needs in the treatment […]

Colorectal Cancer

Thierry André, ASCO20: Phase III KEYNOTE-177 Trial of Pembrolizumab in Metastatic Colorectal Cancer

touchONCOLOGY were delighted to speak with Dr Thierry André to discuss the interim analysis of the randomised open-label phase III KEYNOTE-177 trial (Clinicaltrials.gov identifier: NCT02563002) comparing the programmed cell death protein antibody pembrolizumab with standard-of-care chemotherapy. The data was presented at the ASCO20 Virtual annual meeting. Questions 1. What are the limitations of the current standard […]

Breast Cancer

Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer

Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer. Questions 1. What are the major unmet needs in the treatment of triple-negative […]

Breast Cancer

Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial

We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]

Multiple Myeloma

Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]

FILTER YOUR SEARCH

Speciality: